You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 9,567,370


✉ Email this page to a colleague

« Back to Dashboard


Title:Therapeutic agents for reducing parathyroid hormone levels
Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein the X.sub.1 subunit comprises a thiol-containing moiety and the distribution of charge on the X.sub.2-X.sub.7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Inventor(s): Karim; Felix (Walnut Creek, CA), Baruch; Amos (San Francisco, CA), Maclean; Derek (Los Altos, CA), Das; Kanad (San Francisco, CA), Yin; Qun (Palo Alto, CA)
Assignee: KAI PHARMACEUTICALS, INC. (South San Francisco, CA)
Filing Date:Mar 04, 2015
Application Number:14/639,020
Claims:1. A compound comprising a peptide 8 to 15 amino acids in length comprising the amino acid sequence X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein: X.sub.1 is L-cysteine or D-cysteine, X.sub.2 is D-alanine or D-arginine, X.sub.3 is D-arginine, X.sub.4 is D-alanine or D-arginine, X.sub.5 is D-arginine, X.sub.6 is D-alanine, and X.sub.7 is D-arginine.

2. The compound of claim 1, wherein the peptide is 8 to 11 amino acids in length.

3. The compound of claim 1, wherein the peptide comprises the amino acid sequence X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein: X.sub.2 is D-alanine, X.sub.3 is D-arginine, X.sub.4 is D-arginine, X.sub.5 is D-arginine, X.sub.6 is D-alanine, and X.sub.7 is D-arginine.

4. The compound of claim 1, wherein the N-terminus of the peptide is acetylated.

5. The compound of claim 1, wherein the C-terminus of the peptide is amidated.

6. The compound of claim 1, wherein the N-terminus of the peptide is acetylated and the C-terminus of the peptide is amidated.

7. The compound of claim 1, wherein X.sub.1 is conjugated to a conjugating group via a disulfide bond.

8. The compound of claim 7, wherein the conjugating group is selected from the group consisting of cysteine, homocysteine, glutathione, pegylated cysteine and a thiol-containing polypeptide.

9. The compound of claim 7, wherein the conjugating group is L-cysteine.

10. The compound of claim 7, wherein the conjugating group is D-cysteine.

11. The compound of claim 3, wherein the N-terminus of the peptide is acetylated.

12. The compound of claim 3, wherein the C-terminus of the peptide is amidated.

13. The compound of claim 3, wherein the N-terminus of the peptide is acetylated and the C-terminus of the peptide is amidated.

14. The compound of claim 3, wherein X.sub.1 is conjugated to a conjugating group via a disulfide bond.

15. The compound of claim 14, wherein the conjugating group is selected from the group consisting of cysteine, homocysteine, glutathione, pegylated cysteine and a thiol-containing polypeptide.

16. The compound of claim 14, wherein the conjugating group is L-cysteine.

17. The compound of claim 14, wherein the conjugating group is D-cysteine.

18. A pharmaceutical composition comprising the compound of claim 1.

19. A pharmaceutical composition comprising the compound of claim 3.

20. A method of treating secondary hyperparathyroidism (SHPT) in a subject, comprising administering to the subject a therapeutically effective amount of the compound according to claim 1.

21. The method of claim 20, wherein the subject is suffering from chronic kidney disease.

22. The method according to claim 20, wherein the administering is intravenous.

23. A method of treating secondary hyperparathyroidism (SHPT) in a subject, comprising administering to the subject a therapeutically effective amount of the compound according to claim 3.

24. The method of claim 23, wherein the subject is suffering from chronic kidney disease.

25. The method according to claim 23, wherein the administering is intravenous.

26. The compound of claim 2, wherein the peptide comprises the amino acid sequence X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein: X.sub.2 is D-alanine, X.sub.3 is D-arginine, X.sub.4 is D-arginine, X.sub.5 is D-arginine, X.sub.6 is D-alanine, and X.sub.7 is D-arginine.

27. The compound of claim 1, wherein the peptide comprises the amino acid sequence X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein: X.sub.2 is D-arginine, X.sub.3 is D-arginine, X.sub.4 is D-alanine, X.sub.5 is D-arginine, X.sub.6 is D-alanine, and X.sub.7 is D-arginine.

28. The compound of claim 2, wherein the peptide comprises the amino acid sequence X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein: X.sub.2 is D-arginine, X.sub.3 is D-arginine, X.sub.4 is D-alanine, X.sub.5 is D-arginine, X.sub.6 is D-alanine, and X.sub.7 is D-arginine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.